This Book Is Designed To Introduce New Entrants In The Field Of Critical Care Medicine To Its Clinical Intricacies While Also Enabling Experienced Practitioners To Update Their Skills. It Comprehensively Covers Topics Such As The Role Of Sodium Glucose Cotransporter-2 (Sglt-2) Inhibitors and Sovateltide In Critically Ill Patients, The Application Of Ultrasound For Nutritional Assessment, and Intensive Care In The Era Of Molecular-Targeted Therapies. The Text Further Explores Subphenotyping In Critical Care Medicine, Revisits The Concept Of “Organ Cross” Talk In The Critically Ill, and Addresses Often-Neglected Areas Such As Gut Failure In The Icu. Emerging Domains, Including Frailty and Respiratory Sarcopenia In Critically Ill Patients and The Identification Of New Biomarkers, Are Also Discussed. Additionally, The Book Examines The Potential Impact Of Molecular-Targeted Therapies On Future Critical Care Practice, Extracorporeal Therapy In Toxicology, Management Of The Physiologically Difficult Airway, The Environmental Implications Of Critical Care Units With Respect To The Greenhouse Effect, and Advances In Newer Therapies For Myasthenia Gravis.
Recent Advances in Critical Care Medicine 2025 (Volume 2) – 1st Edition
A Practical Reference Covering Essential Principles For Emergency and Critical Care.
Additional information
| Weight | 0.46 kg |
|---|---|
| Dimensions | 15.88 × 24.13 × 1.39 cm |
| ISBN | 9789372029666 |
| Author | Atul Prabhakar Kulkarni |
| Publisher | Jaypee Brothers Medical Publisher |
| Edition | 1st Edition |
| Pages | 278 |
| Language | English |
| Binding | Paperback |
| Copyright year | 2026 |
25 in stock
Original price was: ₹1,775.00.₹1,154.00Current price is: ₹1,154.00.
| Weight | 0.46 kg |
|---|---|
| Dimensions | 15.88 × 24.13 × 1.39 cm |
| ISBN | 9789372029666 |
| Author | Atul Prabhakar Kulkarni |
| Publisher | Jaypee Brothers Medical Publisher |
| Edition | 1st Edition |
| Pages | 278 |
| Language | English |
| Binding | Paperback |
| Copyright year | 2026 |



Reviews
There are no reviews yet.